> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FTC Challenges Teva Orange Book Listings
- URL: https://www.fdaweb.com/ftc-challenges-teva-orange-book-listings/
- Published: 2024-03-22T12:00:00.000Z
- Updated: 2026-09-14T14:26:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156616

The Federal Trade Commission has [filed an amicus brief](https://www.ftc.gov/legal-library/browse/amicus-briefs/teva-pharmaceuticals-usa-inc-v-amneal-pharmaceuticals-inc?ref=fdaweb.com) calling out Teva Pharmaceuticals for “improperly listed patents” in FDA’s *Orange Book* and urging the court to order them removed. “Improper *Orange Book* listings can harm competition by delaying the entry of cheaper generic products,” according to the brief. The filing is in response to a case brought by Teva against drugmaker Amneal after Amneal sought approval of a generic version of asthma inhaler ProAir HFA.

Amneal argues that Teva improperly listed its patents in the *Orange Book* and therefore should not be able to stay approval of Amneal’s competing generic product. In its brief, FTC says the court should grant Amneal’s motion for judgment to compel de-listing of the patents at issue.

Lately, FTC has been taking a tougher stance against improper patent listings. In November, [it challenged](https://www.ftc.gov/news-events/news/press-releases/2023/11/ftc-challenges-more-100-patents-improperly-listed-fdas-orange-book?ref=fdaweb.com) over 100 patent-listings as improperly listed, including the five patents at issue in Teva’s case against Amneal, as well as 37 additional Teva patentlistings.